title: FDG-PET/CT in abdominal post-transplant lymphoproliferative disease.
abstract: Post-transplant lymphoproliferative disease (PTLD) is a major cause of morbidity and mortality following both solid organ and haematopoietic stem cell transplantation. PTLD has a broad range of manifestations with extranodal involvement more common in the abdomen than nodal involvement. Fludeoxyglucose positron emission tomography/CT (FDG-PET/CT) is sensitive and specific to detect PTLD and can upstage or detect occult PTLD compared with conventional CT imaging. As functional imaging, FDG-PET/CT also has a role in monitoring treatment response. In this pictorial essay, we will discuss the role of FDG-PET/CT in the diagnosis and staging of abdominal PTLD and describe the advantages of functional imaging in assessing response to therapy.
authors.affiliation: Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, ON, Canada.
authors.forename: Ur
authors.initials: U
authors.lastname: Metser
authors.affiliation: Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, ON, Canada.
authors.forename: Glen
authors.initials: G
authors.lastname: Lo
mesh_terms: D000005:Abdomen / Q000000981:diagnostic imaging; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000175:diagnosis*; D064847:Multimodal Imaging; D016377:Organ Transplantation; D049268:Positron-Emission Tomography; D011183:Postoperative Complications / Q000175:diagnosis*; D011860:Radiography, Abdominal; D019275:Radiopharmaceuticals; D033581:Stem Cell Transplantation; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18